Pharma

FDA advisers support new Alzheimer's drug to slow progression

FDA advisers back Eli Lilly's Alzheimer's drug donanemab, citing its benefits over risks like brain swelling

FDA advisers support new Alzheimer's drug to slow progression

Canada advances universal pharmacare with Bill C-64

Bill C-64 passes in House of Commons, paving the way for a $1.5bn universal pharmacare program

Canada advances universal pharmacare with Bill C-64

Should plan sponsors include coverage for obesity drugs?

According to Manulife's Employee Health Report, employees are increasingly using anti-obesity meds

Should plan sponsors include coverage for obesity drugs?

Canada licenses psychedelic exports to Australia

Optimi Health can now export psilocybin and MDMA to Australia, marking a key step in the medical psychedelics market

Canada licenses psychedelic exports to Australia

Study validates promises of key GLP-1 drug for diabetics

A new study shows that semaglutide lowers risks of major kidney and heart events in diabetes patients

Study validates promises of key GLP-1 drug for diabetics

Canadian real estate shows resilience in Q1 2024

Canada's commercial real estate remains strong in Q1 2024 despite slowing investment sales activity

Canadian real estate shows resilience in Q1 2024